Vera Therapeutics (VERA) Operating Leases (2022 - 2025)

Vera Therapeutics has reported Operating Leases for 4 years, with the latest figure at $1.9 million in Q4 2025.

• For the quarter ending Q4 2025, Operating Leases fell 22.24% year-over-year to $1.9 million; the trailing twelve-month figure through Dec 2025 stood at $1.9 million (down 22.24% YoY), and the FY2025 full-year result was $1.9 million, down 22.24% from the prior year.
• Operating Leases for Q4 2025 stood at $1.9 million, down from $2.1 million in the prior quarter.
• The five-year high for Operating Leases was $5.4 million in Q1 2022, with the low at $455000.0 in Q2 2024.
• Historically, Operating Leases has averaged $2.7 million across 4 years, with a median of $2.4 million in 2024.
• Annual changes were most pronounced in 2024 — Operating Leases plunged 82.3% — and 2025, when it surged 390.77%.
• Vera Therapeutics' Operating Leases stood at $3.8 million in 2022, then plunged by 63.59% to $1.4 million in 2023, then soared by 76.92% to $2.5 million in 2024, then dropped by 22.24% to $1.9 million in 2025.
• The last three Operating Leases figures came in at $1.9 million (Q4 2025), $2.1 million (Q3 2025), and $2.2 million (Q2 2025), per Business Quant data.